02931nas a2200289   4500008004100000020001400041024001700055245014100072210006900213260031700282300001400599490000700613520169900620653003402319653003002353653003902383100001802422700001902440700002202459700001902481700001802500700002202518700001702540700001902557700002002576856004502596       2002                        eng d  a0902-0063  abb5, 871024000aPrevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.0 aPrevention of de novo hepatitis B virus infection in living dono  a(C) 2002 Munksgaard International Publishers Ltd.b(a)Department of Surgery, Liver Transplant Program, Chang Gung University, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan(b)Department of Diagnostic Radiology, Liver Transplant Program, Chang Gung University, Chang Gung Memorialc2002  a405 - 4090 v163 aExclusion of liver grafts from hepatitis B core antibody (anti-HBc) positive donors to prevent de novo hepatitis B virus (HBV) infection after liver transplantation is not feasible in areas highly endemic for HBV virus like Taiwan, where approximately 80% of adults are anti-HBc(+). The efficacy of lamivudine monotherapy to prevent de novo HBV infection after living donor liver transplantation (LDLT) using grafts from anti-HBc(+) donors remains to be elucidated. From June 1994 to August 2000, LDLT was performed in 42 recipients. Twenty-four of the 42 donors were anti-HBc(+) (57%). Pre-transplant HBV vaccination was given to all recipients irrespective of anti-HBc status at monthly intervals for 3 months. Until December 1997, eight recipients received liver grafts from anti-HBc(+) donors without prophylaxis. Since January 1998, prophylaxis with lamivudine monotherapy was given to 16 recipients receiving liver grafts from anti-HBc(+) donors. De novo HBV infection occurred in three of the eight recipients (37.5%) who did not receive prophylaxis, while none of the 16 recipients given lamivudine developed de novo HBV infection after a mean follow-up of 25 months. Two of the three recipients with de novo HBV infection were anti-HBs(-) and one recipient was anti-HBs(+). Lamivudine was well tolerated, and no side effects were noted. These results suggest that lamivudine monotherapy for recipients receiving anti-HBc(+) liver grafts is a simple, relatively inexpensive and effective prophylactic regimen for prevention of de novo HBV infection. The additive protection provided by vaccine-induced or natural immunity is uncertain., (C) 2002 Munksgaard International Publishers Ltd.10ade novo hepatitis B infection10ahepatitis B core antibody10aliving donor liver transplantation1 aChen, Yaw-Sen1 aWang, Chih-Chi1 ade Villa, Vanessa1 aWang, Shih-Hor1 aCheng, Yu-Fan1 aHuang, Tung-Liang1 aJawan, Bruno1 aChiu, King-Wah1 aChen, Chao-Long  uhttp://613633.bywedr.asia/reference/4051